Cytomegalovirus (CMV) reactivation has been widely documented in the past 10 years in critically ill patients [1] . Conversely, few data are available on burn patients despite experimental studies showing that these patients are predisposed to herpes virus infections [2] . To our knowledge, only two studies reported the incidence of CMV infection in burn patients using a modern technique, such as PCR, which has become the gold standard [3, 4] . Th ese two studies demonstrated a high rate of CMV reactivation, 55% and 71%, respectively. Moreover, CMV reactivation in burn patients has been proven to be intense. Indeed, in the study of Bordes and colleagues [4] , 67% of patients who reactivated CMV experienced viremia greater than 1,000 copies/ml, and 33% viremia greater than 10,000 copies/ml. Th ese results may refl ect the severe immunosuppression that characterizes thermally injured patients. Consequently, severe burn patients could be considered as a model for CMV reactivation in critically ill patients. However, the precise kinetics of CMV DNA load in these patients is still poorly docu mented. Th at is why we would like to briefl y present data from longitudinal monitoring of CMV infection by real-time PCR (RT-PCR) in four severe burn patients during their ICU stay ( Figure 1 ).
All the patients were CMV IgG seropositive on admission. Th ey were monitored for CMV reactivation once to twice a week. Detection of CMV DNA in blood samples was performed by quantitative RT-PCR on whole blood. Th e patients' characteristics are described in Table 1 . Patient 2 presented a CMV-associated hemophagocytic syndrome and was treated by ganciclovir for a duration of 21 days. DNAemia became undetectable in patients 3 and 4 spontaneously. Th ese examples demonstrate that critically ill patients may experience several episodes of CMV reactivation during their ICU stay, and that CMV viral load can be very changeable. Furthermore, CMV viremia may be highly variable over a short period.
In our opinion, CMV reactivation in critically ill patients should be monitored with quantitative methods of detection, such as RT-PCR. Indeed, we hypothesize that the potential role of CMV on patient outcome is mostly due to the intensity of CMV reactivation rather than the CMV reactivation per se. Th at is why we suggest that studies aimed at determining the role of CMV reactivation as a contributor to outcome in critically ill patients should use quantitative methods of detection. Consequently, a CMV viremia threshold could be determined to guide preemptive therapy in these patients.
Written consent for publication was obtained from the patients or patients' relatives.
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